Lantern Pharma (LTRN) Tops Q3 EPS by 14c

Lantern Pharma (NASDAQ: LTRN) reported Q3 EPS of ($0.42), $0.14 better than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• BNP Paribas Exane Downgrades Alcon Inc. (ALC:SW) (ALC) to Neutral
• Faraday Future stockholders approve $25M private placement proposal